Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone

Multiple myeloma (MM), as well as some treatments for MM, increase the risk of venous thromboembolism (VTE). Prior literature suggests carfilzomib, lenalidomide, and dexamethasone (KRd) may have a higher incidence of thromboembolic events compared with bortezomib, lenalidomide, and dexamethasone (VRd). We aimed to evaluate VTE risk with KRd induction compared to VRd at a large academic medical center in the United States.

Source: Clinical Lymphoma, Myeloma and Leukemia - July 22, 2023 Category: Hematology Authors: Alexa J. Loncharich, Mark A. Fiala, Michael J. Slade, Angela Vickroy, Margaret Kavanaugh, Carmen Wilson, Mark A. Schroeder, Keith Stockerl-Goldstein, Ravi Vij, Kristen M. Sanfilippo Tags: Original Study Source Type: research